The Teva Pharmaceutical Industries Ltd (TEVA) Cut to “Buy” at Vetr Inc.

The Teva Pharmaceutical Industries Ltd (TEVA) Cut to “Buy” at Vetr Inc.

Several other equities analysts have also recently weighed in on the company. Zacks Investment Research raised Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research report on Monday, April 17th. Cowen and Company reissued an “outperform” rating and set a $50.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Tuesday, April 4th. Citigroup Inc cut their price objective on Teva Pharmaceutical Industries from $47.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, April 25th. Maxim Group reissued an “outperform” rating and set a $35.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 29th. Finally, Deutsche Bank AG cut their price objective on Teva Pharmaceutical Industries from $45.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, May 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $43.91.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was downgraded by equities researchers at Vetr from a “strong-buy” rating to a “buy” rating in a research report issued on Monday. They currently have a $32.04 price target on the stock. Vetr‘s price target points to a potential upside of 10.37% from the stock’s previous close.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 29.03 on Monday. Teva Pharmaceutical Industries has a 52 week low of $27.60 and a 52 week high of $56.44. The firm has a market cap of $29.49 billion, a price-to-earnings ratio of 372.18 and a beta of 0.58. The firm’s 50-day moving average price is $30.54 and its 200-day moving average price is $33.79.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting the consensus estimate of $1.06. Teva Pharmaceutical Industries had a return on equity of 17.46% and a net margin of 1.50%. The business had revenue of $5.63 billion during the quarter, compared to analysts’ expectations of $5.69 billion. During the same quarter in the previous year, the firm earned $1.20 EPS. The firm’s revenue was up 17.0% compared to the same quarter last year. Equities research analysts expect that Teva Pharmaceutical Industries will post $4.79 EPS for the current fiscal year. The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 22nd. Investors of record on Monday, June 5th will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, June 1st. This represents a $1.36 dividend on an annualized basis and a yield of 4.68%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently 1,657.38%.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting the consensus estimate of $1.06. Teva Pharmaceutical Industries had a return on equity of 17.46% and a net margin of 1.50%. The business had revenue of $5.63 billion during the quarter, compared to analysts’ expectations of $5.69 billion. During the same quarter in the previous year, the firm earned $1.20 EPS. The firm’s revenue was up 17.0% compared to the same quarter last year. Equities research analysts expect that Teva Pharmaceutical Industries will post $4.79 EPS for the current fiscal year. A number of large investors have recently added to or reduced their stakes in the company. Schulhoff & Co. Inc. raised its stake in Teva Pharmaceutical Industries by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock worth $372,000 after buying an additional 1,004 shares during the period. Heritage Investors Management Corp raised its stake in Teva Pharmaceutical Industries by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock worth $6,065,000 after buying an additional 28,135 shares during the period. M Holdings Securities Inc. acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth approximately $491,000. Bank Hapoalim BM raised its stake in Teva Pharmaceutical Industries by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after buying an additional 980 shares during the period. Finally, Lincluden Management Ltd. raised its stake in Teva Pharmaceutical Industries by 7.8% in the fourth quarter. Lincluden Management Ltd. now owns 58,854 shares of the company’s stock worth $2,133,000 after buying an additional 4,272 shares during the period. Institutional investors and hedge funds own 55.03% of the company’s stock.

About Teva Pharmaceutical Industries Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “TEVA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment